Abstract:Nonalcoholic steatohepatitis (NASH) arises from a variable interplay between environmental factors and genetic determinants that cannot be completely replicated in animals. Notwithstanding, preclinical models are needed to understand NASH pathophysiology and test mechanism-based therapies. Among several mouse models of NASH, some exhibit the key pathophysiologic as well as histopathologic criteria for human NASH, whereas others may be useful to address specific questions. Models based on overnutrition with adipose restriction/inflammation and metabolic complications, particularly insulin resistance, may be most useful to investigate critical etiopathogenic factors. In-depth pathologic description is required for all models. Some models demonstrate hepatocyte ballooning, which can be confused with microvesicular steatosis, whereas demonstration of an inflammatory infiltrate and pattern of liver fibrosis compatible with human NASH is desirable in models used for pharmacologic testing. When mice with specific genetic strains or mutations that cause overeating consume a diet enriched with fat, modest amounts of cholesterol, and/or simple sugars ("Western diet"), they readily develop obesity with liver disease similar to human NASH, including significant fibrosis. Purely dietary models, such as high-fat/high-cholesterol, Western diet, and choline-deficient, amino acid-defined, are similarly promising. We share concern about using models without weight gain, adipose pathology, or insulin resistance/hyperinsulinemia and with inadequate documentation of liver pathology. NASH-related fibrosis is a key endpoint in trials of possible therapies. When studied for this purpose, NASH models should be reproducible and show steatohepatitis (ideally with ballooning) and at least focal bridging fibrosis, while metabolic factors/disordered lipid partitioning should contribute to etiopathogenesis. Because murine models are increasingly used to explore pharmacologic therapies for NASH, we propose a minimum set of requirements that investigators, drug companies, and journals should consider to optimize their translational value.

Utilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinoma.

Pathogenesis of and Major Animal Models Used for Nonalcoholic Fatty Liver Disease

NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments

Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Comparison of Animal Models for the Study of Nonalcoholic Fatty Liver Disease

Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis

Rodent Models of Nonalcoholic Fatty Liver Disease

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology

Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis

Commonly used animal models of non-alcoholic steatohepatitis.

Endoplasmic Reticulum Stress and Lipophagy in Nonalcoholic Steatohepatitis

Mouse models of nonalcoholic steatohepatitis and their application to new drug development

Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis

A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response

Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies

Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water

A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice

Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors

An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis

Targeted Inhibition of LPL/FABP4/CPT1 Fatty Acid Metabolic Axis Can Effectively Prevent the Progression of Nonalcoholic Steatohepatitis to Liver Cancer.